These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events Lancet; 2001 Mar; 357(9261):995-1001. PubMed ID: 11293642 [TBL] [Abstract][Full Text] [Related]
5. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Vittinghoff E; Shlipak MG; Varosy PD; Furberg CD; Ireland CC; Khan SS; Blumenthal R; Barrett-Connor E; Hulley S; Ann Intern Med; 2003 Jan; 138(2):81-9. PubMed ID: 12529088 [TBL] [Abstract][Full Text] [Related]
6. Status of secondary prevention in patients undergoing coronary revascularization. Allen JK; Blumenthal RS; Margolis S; Young DR Am J Cardiol; 2001 May; 87(10):1203-6: A7. PubMed ID: 11356400 [No Abstract] [Full Text] [Related]
7. Cost effectiveness of coronary heart disease prevention strategies in adults. Brown AD; Garber AM Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193 [TBL] [Abstract][Full Text] [Related]
8. [Secondary prevention of coronary heart disease. How effective are modern therapy methods?]. Kolenda KD Dtsch Med Wochenschr; 2003 Sep; 128(36):1849-53. PubMed ID: 12964107 [No Abstract] [Full Text] [Related]
9. Secondary prevention of coronary heart disease in the elderly. Bulpitt CJ Heart; 2005 Mar; 91(3):396-400. PubMed ID: 15710740 [No Abstract] [Full Text] [Related]
10. Secondary prevention of coronary heart disease in the elderly. Dornbrook-Lavender KA; Roth MT; Pieper JA Ann Pharmacother; 2003 Dec; 37(12):1867-76. PubMed ID: 14632542 [TBL] [Abstract][Full Text] [Related]
11. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. Isles CG; Paterson JR QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551 [TBL] [Abstract][Full Text] [Related]
12. Sudden cardiac death in ischemic heart disease. Chang D; Goldstein S Compr Ther; 1997 Feb; 23(2):95-103. PubMed ID: 9083719 [No Abstract] [Full Text] [Related]
13. Trials of lipid-lowering therapy in primary prevention of coronary heart disease. Jones PH Curr Opin Lipidol; 1995 Dec; 6(6):365-8. PubMed ID: 8750249 [TBL] [Abstract][Full Text] [Related]
14. Summaries for patients. Risk factors and treatment in women with coronary artery disease. Ann Intern Med; 2003 Jan; 138(2):I10. PubMed ID: 12529114 [No Abstract] [Full Text] [Related]
15. [Methods of reporting research-results and their influence on decision-making by cardiologists prescribing drugs for primary and secondary prevention]. Brotons C; Moral I; Ribera A; Cascant P; Iglesias M; Permanyer-Miralda G; Ferreira González I; Soler-Soler J Rev Esp Cardiol; 2002 Oct; 55(10):1042-51. PubMed ID: 12383389 [TBL] [Abstract][Full Text] [Related]
17. Heartwatch: a secondary prevention programme in primary care in Ireland. Bennett K; Jennings S; Collins C; Boland M; Leahy J; Bedford D; Shelley E Eur J Cardiovasc Prev Rehabil; 2008 Dec; 15(6):651-6. PubMed ID: 19177599 [TBL] [Abstract][Full Text] [Related]
18. Nonlipid primary and secondary prevention strategies for coronary heart disease. Maron DJ Clin Cardiol; 1996 May; 19(5):419-23. PubMed ID: 8723603 [TBL] [Abstract][Full Text] [Related]
19. Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. Steg PG; Iung B; Feldman LJ; Cokkinos D; Deckers J; Fox KA; Keil U; Maggioni AP Heart; 2002 Jul; 88(1):20-4. PubMed ID: 12067934 [TBL] [Abstract][Full Text] [Related]